Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand

Japanese Journal of Infectious Diseases

Volumn 59, Issue 3, 2006, Pages 168-173

  Ono, Shunsuke ^a,b   Kurotaki, Takako ^a   Nakasone, Tadashi ^c   Honda, Mitsuo ^c   Boon Long, Jotika ^d   Sawanpanyalert, Pathom ^d   Kimura, Kazuko ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG EFFICACY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROBABILITY; SCHOOL CHILD; SENSITIVITY ANALYSIS; STATISTICAL MODEL; THAILAND; VACCINATION;

ADOLESCENT; ADULT; AIDS VACCINES; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MARKOV CHAINS; THAILAND;

EID: 33745491823     PISSN: 13446304     EISSN: 13446304     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Joint United Nations Programme on HIV/AIDS (2004): AIDS epidemic updates. December 2004. Online at . A ccessed 4 August 2005.
2. Bos, J. M. and Postma, M. J. (2001): The economics of HIV vaccines. Pharmacoeconomics, 19, 937-946.
3. Joint United Nations Programme on HIV/AIDS (1999): AIDS vaccine research in Asia: needs and opportunities. AIDS, 13, 1-13.
4. Ruxrungtham, K., Brown, T. and Phanuphak, P. (2004): HIV/AIDS in Asia. Lancet, 364, 69-82.
5. World Health Organization (2003): The WHO and UNAIDS global initiative to provide antiretroviral therapy to 3 million people with HIV/AIDS in developing countries by the end of 2005. Geneva, Switzerland.
6. Kraisintu, K. (2002): Generic production of HIV/AIDS-related drugs in Thailand. Abstract (MoOrg1038). 14th International AIDS Conference. Barcelona, July 2002.
7. Anekthananon, T., Ratanasuwan, W., Techasathit, W., Techasathit, W., Sonjai, A. and Suwanagool, S. (2004): Safety and efficacy of a simplified fixed-dose combination of stavudine, lamibudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients. J. Med. Assoc. Thai., 87, 760-767.
8. International AIDS Vaccine Initiative (2005): IAVI database of AIDS vaccines in human trials. Online at . Accessed 4 August 2005.
9. Tangcharoensathien, V., Phoolcharoen, W., Pitayarangsarit, S., Kongsin, S., Kasemsup, V., Tantivess, S. and Suraratdecha, C. (2001): The potential demand for an AIDS vaccine in Thailand. Health Policy, 57, 111-139.
10. McCarthy, M. (2003): HIV vaccine fails in phase 3 trials. Lancet, 361, 755-756.
11. VaxGen (2003): VaxGen announces results of its Phase 3 HIV vaccine trial in Thailand: Vaccine fails to meet endpoints (Nov 12, 2003). Online at . Accessed 4 August 2005.
12. The rgp 120 HIV Vaccine Study Group (2005): Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis., 191, 654-665.
13. Burton, D. R., Desrosiers, R. C., Doms, R. W., Feinberg, M. B., Gallo, R. C., Hahn, B., Hoxie, J. A., Hunter, E., Korber, B. and Landay, A. (2004): A sound rationale needed for phase III HIV-1 vaccine trials. Science, 303, 316.
14. Mitka, M. (2003): Critics bash HIV vaccine trial analysis. JAMA, 289, 1491.
15. Matsuo, K., Puthavathana, P., Promkhatkaew, D., Balachandra, K., Ruxrungtham, K., Hamano, T., Sutthent, R., Sittisombut, N., Butraporn, R., Sriwanthana, B., Boonlong, J., Izumi, Y., Yamazaki, S., Yamamoto, N, Warachit, P. and Honda, M. (2004): Japan's collaboration with Thailand in the development of an HIV/AIDS vaccine. p. 561-569. In Lu, Y. and Essex, M. (eds.), AIDS in Asia. Plenum US, New York.
16. Someya, K., Xin, K. Q., Matsuo, K., Okuda, N., Yamamoto, N. and Honda, M. (2004): A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity. J. Virol., 78, 9842-9853.
17. The Thai Working Group on HIV/AIDS Projection (2001): Projection for HIV/ AIDS in Thailand: 2000-2003. Karnsana Printing Press, Bangkok.
18. National Institute of Allergy and Infectious Diseases (2001): AIDS vaccine trials: considerations for Phase III trial design and endpoints. Online at . Accessed 4 August 2005.
19. Yeni, P. G., Hammer, S. M., Carpenter, C. C. J., Cooper, D.A., Fischl, M.A., Gatell, J. M., Gazzard, B. G., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., Richman, D. D., Saag, M. S., Schechter, M., Schooley, R. T., Thompson, M. A., Vella, S. and Volberding, P. A. (2002): Antiretroviral treatment for adult HIV infection in 2002. JAMA, 288, 222-225.
20. Miners, A. H., Sabin, C. A., Trueman, P., Youle, M., Mocroft, A., Johnson, M. and Beck, E. J. (2001): Assessing the cost-effectiveness of highly active antiretoroviral therapy for adults with HIV in England. HIV Med., 2, 52-58.
21. VISION/VAX004 Study Team (2005): HIV sexual risk behavior over 36 months of follow-up in the world's first HIV efficacy trial. J. Acquir. Immune Defic. Syndr., 39, 90-101.
22. Little, S. J., Holte, S., Routy, J. P., Daar, E. S., Markowitz, M., Collier, A. C., Koup, R. A., Mellors, J. W., Connick, E., Conway, B., Kilby, M., Wang, L., Whitcomb, J. M., Hellmann, N. S. and Richman, D. D. (2002): Antiretroviral-drug resistance among patients recently infected with HIV. N. Eng. J. Med., 347, 385-394.
23. Omori, K. (1998): Assessment of the effectiveness of NGO-implemented HIV/ AIDS work for persons living with HIV in Northern Thailand. Hokuriku J. Public Health, 25, 79-87.
24. Kamolratanakul, P., Chuhaswasdikul, B., Jittinandana, A., Tangcharoensathien, V., Udomrati, N. and Akksilp, S. (1993): Cost-effectiveness analysis of three short-course anti-tuberculosis programs compared with a standard regimen in Thailand. J. Clin. Epidemiol., 46, 631-636.
25. Teokul, W. (2002). An assessment of Thailand's potential in financing HIV/AIDS care. Online at . Accessed 3 December 2002.
26. Ainsworth, M. and Teokul, W. (2000): Breaking the silence: setting realistic priorities for AIDS control in less developed countries. Lancet, 356, 55-60.
27. Murray, C. J. L. (1994): Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull. World Health Organ., 72, 429-445.
28. Fox-Rushby, J. A. and Hanson, K. (2001): Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan., 16, 326-331.
29. Creese, A., Floyd, K., Alban, A. and Guinness, L. (2002): Cost-effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet, 359, 1635-1642.
30. Briggs, A. H. (2001): Handling uncertainty in economic evaluation and presenting the results. p. 172-214. In Drummond, M. and McGuire, A. (eds.), Economic Evaluation in Health Care. Oxford University Press, New York.
31. Esparza, J., Osmanov, S., Markovic, C. P., Toure, C., Chang, M. L. and Nixon, S. (2002): Past, present and future of HIV vaccine trials in developing countries. Vaccine, 20, 1897-1899.
32. Makgoba, M. W., Solomon, N. and Tucker, T. J. P. (2002): The search for an HIV vaccine. Br. Med. J., 324, 211-213.
33. Walker, D. (2003): Cost and cost-effectiveness of HIV/AIDS prevention strategies in developing countries. Health Policy Plan., 18, 4-17.
34. Teerawattananon, Y., Vos, T., Tangcharoensathien, V. and Mugford, M. (2005): Cost-effectiveness of models for prevention of vertical HIV transmission - voluntary counseling and testing and choices of drug regimen. Cost Eff. Resour. Alloc., 3, 7.
35. Thaineua, V., Sirinirund, P., Tanbanjong, A., Lallelmant, M., Soucat, A. and Lamboray, J.-L. (1998): From research to practice: use of short course zidovudine to prevent mother-to-child HIV transmission in the context of routine health care in northern Thailand. Southeast Asian J. Trop. Med. Public Health, 29, 429-442.
36. Cowley, P. (1993): Preliminary cost-effectiveness analysis of an AIDS vaccine in Abidjan, Ivory Coast. Health Policy, 24, 145-153.